(NASDAQ: MAZE) Maze Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Maze Therapeutics's earnings in 2025 is $3,405,000.On average, 3 Wall Street analysts forecast MAZE's earnings for 2025 to be -$120,439,157, with the lowest MAZE earnings forecast at -$142,337,185, and the highest MAZE earnings forecast at -$102,044,813. On average, 3 Wall Street analysts forecast MAZE's earnings for 2026 to be -$127,446,526, with the lowest MAZE earnings forecast at -$155,476,002, and the highest MAZE earnings forecast at -$105,110,537.
In 2027, MAZE is forecast to generate -$127,665,506 in earnings, with the lowest earnings forecast at -$143,651,067 and the highest earnings forecast at -$111,679,945.